MedPath

Riluzole

Generic Name
Riluzole
Brand Names
Exservan, Rilutek, Tiglutik, Riluzole Zentiva
Drug Type
Small Molecule
Chemical Formula
C8H5F3N2OS
CAS Number
1744-22-5
Unique Ingredient Identifier
7LJ087RS6F
Background

A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.

Indication

For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

Associated Conditions
Amyotrophic Lateral Sclerosis (ALS)
Clinical Trials
Related News

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2
Completed
Conditions
Melanoma (Skin)
Interventions
First Posted Date
2009-03-23
Last Posted Date
2024-01-19
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
13
Registration Number
NCT00866840
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

Phase 2
Terminated
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: placebo
First Posted Date
2009-01-07
Last Posted Date
2011-04-19
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
84
Registration Number
NCT00818389
Locations
🇺🇸

Cedars-Sinai ALS Center, Neurology Specialty Clinic, 8730 Alden Drive, Thalians, E 245, Los Angeles, California, United States

🇺🇸

Ohio State University, Neuromuscular Division, 1654 Uphan Drive, 417 Means Hall, Columbus, Ohio, United States

🇨🇦

University of Saskatchewan, Saskatoon City Hospital, 701 Queen Street, Room 7717 - 7th Floor, Saskatoon, Saskatchewan, Canada

and more 34 locations

Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder

Phase 2
Terminated
Conditions
Bipolar Depression
Bipolar Disorder
Anxiety Disorders
Bipolar Affective Disorder
Interventions
First Posted Date
2008-12-09
Last Posted Date
2017-09-15
Lead Sponsor
National Institute of Mental Health (NIMH)
Target Recruit Count
6
Registration Number
NCT00805493
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA)

Phase 2
Completed
Conditions
SMA
Interventions
First Posted Date
2008-10-17
Last Posted Date
2013-02-15
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
141
Registration Number
NCT00774423
Locations
🇫🇷

Hopital Raymond Poincare, Garches, France

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Phase 1
Terminated
Conditions
Melanoma (Skin)
First Posted Date
2008-04-28
Last Posted Date
2009-12-11
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
15
Registration Number
NCT00667901
Locations
🇺🇸

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Riluzole in the Treatment of Bipolar Depression

Not Applicable
Completed
Conditions
Bipolar Depression
Interventions
First Posted Date
2007-10-16
Last Posted Date
2018-08-07
Lead Sponsor
Mclean Hospital
Target Recruit Count
14
Registration Number
NCT00544544
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

CARE Canadian ALS Riluzole Evaluation

Phase 4
Completed
Conditions
Amyotrophic Lateral Sclerosis
First Posted Date
2007-10-11
Last Posted Date
2007-10-11
Lead Sponsor
Sanofi
Target Recruit Count
414
Registration Number
NCT00542412
Locations
🇨🇦

Sanofi-Aventis, Laval, Quebec, Canada

Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder

Phase 2
Completed
Conditions
Obsessive-compulsive Disorder
Ocd
Interventions
Drug: placebo
First Posted Date
2007-08-31
Last Posted Date
2020-03-06
Lead Sponsor
Yale University
Target Recruit Count
40
Registration Number
NCT00523718
Locations
🇺🇸

Yale OCD Research Clinic, New Haven, Connecticut, United States

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

Phase 2
Completed
Conditions
Multiple Sclerosis
Interventions
Drug: Placebo
First Posted Date
2007-07-16
Last Posted Date
2014-04-09
Lead Sponsor
University of California, San Francisco
Target Recruit Count
43
Registration Number
NCT00501943
Locations
🇺🇸

UCSF MS Center , 675 Nelson Rising Lane, Suite 221, San Francisco, California, United States

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

Phase 4
Completed
Conditions
Major Depression
Interventions
First Posted Date
2007-01-05
Last Posted Date
2019-07-31
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
26
Registration Number
NCT00419003
Locations
🇺🇸

Mount Sinai School of Medicine, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy